Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

psule formulation, greater efficacy and reduced side effects.
  • Sales of Sinobiopharma's formulation of L-alanyl-L-glutamine for parenteral (intravenous) nutrition are projected to exceed 30,000 units in 2009.
  • The Company is in the process of submitting its application for approval of Rocuronium bromide, a next generation skeletal muscle relaxant that is also the first that can be stored at room temperature, to the Chinese Food and Drug Administration (SFDA).

  • "In the first quarter of 2009, we saw strong demand for our existing products," said Lequn Huang, Company President and CEO. "We expect that increased marketing efforts and expanded distribution will help boost additional growth for the rest of 2009, with projected improvements in both margins and profitability."

    About Sinobiopharma

    Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

        Contacts:
        Sinobiopharma, Inc.
        Investor Relations: 1-877-568-0188
    

    FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or resu
    '/>"/>

    SOURCE Sinobiopharma, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
    2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
    3. Sinobiopharma, Inc. Appoints New Director of Marketing
    4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    6. Sinobiopharma Secures Rights to Seven Key Patents
    7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
    8. SemBioSys updates Apo AI development program
    9. Strategic Diagnostics Updates Roth Conference Presentation Time
    10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
    11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/27/2014)... 2014 The Europe Thermal Protective ... to provide crucial revenue forecasts. It estimates the ... at a CAGR of 7.5%, from 2013 to ... Europe Thermal Protective Clothing market report for a ... supported by various tables and figures. , ...
    (Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
    (Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
    (Date:11/27/2014)... November 27, 2014 First ...   Elsevier , a world-leading provider ... is pleased to announce the launch of a new ... The launch of Extreme Mechanics ... at the forefront of applied sciences such as micro ...
    Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
    ... Inc., today,announced the appointment of Lynn Marcus-Wyner, Ph.D., ... for managing the company,s,intellectual property strategy, activities, and ... President, General Counsel and Secretary., Dr. Marcus-Wyner ... Intellectual Assets US, she managed the United States ...
    ... Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) ... terms with Toray,Industries Inc. of Japan to obtain ... for Toraymyxin(TM), a therapeutic for the treatment of,sepsis ... terms of the,agreement, the Company will seek FDA ...
    ... BROOMFIELD, Colo., Sept. 23 ARCA biopharma, ... Drug Administration (FDA) has,accepted a New Drug ... bucindolol, an investigational and pharmacologically unique,beta-blocker and ... chronic,heart failure. If approved by the FDA, ...
    Cached Biology Technology:Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3
    (Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
    (Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
    (Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
    Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
    ... [Brown University] Just as a company creates new, better ... its bottom line, an international team of researchers led by ... and performance before flooding the environment with new, improved versions ... plants with the same ancestor, called a clade, begin to ...
    ... growth and spread of breast cancer tumors may be ... strategies: blocking the enzyme needed to "energize" cancer cells ... with minimum exposure to healthy tissues, indicate researchers at ... in Chicago, Ill. "Once breast cancer metastases ...
    ... with information on the size of the carbon footprint ... make better, environmentally friendly choices. A Michigan State ... of the journal Nature Climate Change , said ... with nutritional information, could offer at least a short-term ...
    Cached Biology News:Like products, plants wait for optimal configuration before market success 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 3Nature paper calls for carbon labeling 2
    ... genetically engineered Klenow polymerase in which the 3 ... only the 5 to 3 polymerase activity. The ... the enzyme of choice for isotopic or biotin ... method, and for DNA sequencing by the Sanger ...
    ... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
    ... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
    Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
    Biology Products: